摘要
目的:观察利培酮口服液合并劳拉西泮治疗精神分裂症急性期的疗效和药物不良反应。方法:将50例精神分裂症急性期患者随机分为研究组和对照组,分别给予利培酮口服液合并劳拉西泮及氟哌啶醇注射液合并氯硝西泮治疗,疗程2周,采用阳性与阴性症状量表(PANSS)评定疗效,副反应量表(TESS)评价不良反应。结果:利培酮口服液合并劳拉西泮与氟哌啶醇注射液合并氯硝西泮对精神分裂症急性期的疗效对比无显著差异(P>0.05),利培酮口服液合并劳拉西泮不良反应少于氟哌啶醇注射液合并氯硝西泮。结论:利培酮口服液合并劳拉西泮控制精神分裂症急性期与氟哌啶醇注射液合并氯硝西泮的疗效相当,而利培酮口服液合并劳拉西泮用药依从性好、不良反应少。
Objective： To observe the treatment effect and medicine untoward effect of schizophrenia acute stage treatment effect by Risperidone oral liquid merged with Lorazepam. Methods ：50 acute schizophrenic patients divided random group who are treated by Risperidone oral liquid merged with Lorazepam and Halopefidol injection merged with Clonazepam within two weeks will he assessed the treatment effect by Positive And Negative Syndrome Scale （PANSS） ,untoward effect by Treatment Emergent Symptom Scale （TESS）. Results：There is no obvious different by the treatment of Risperidone oral liquid merged with Lorazepam and Haloperidol injection merged with Clonazepam （ P 〉 0. 01 ）. The untoward effect of Risperidone oral liquid merged with Lorazepan is less than Haloperidol injection merged with Clonazepam. Conclusion：The treatment effect for these two ways is same. The Rispefidone oral liquid merged with Lorzepan is better at the compliance and less at the untoward effect.
出处
《中国民康医学》
2011年第8期926-926,1032,共2页
Medical Journal of Chinese People’s Health
